Ruohan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruohan Zhang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Fengxia Gao
Pelotonia Institute for Immuno-Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
1 shared publication - Gang Xin
Department of Microbial Infection and Immunity, Ohio State University, Columbus (G.X.).
1 shared publication - Haitao Wen
Department of Microbial Infection and Immunity, Infectious Disease Institute, The Ohio State University
1 shared publication - Jiacheng Jin
Pelotonia Institute for Immuno-Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
1 shared publication Jianying Li
Pelotonia Institute for Immuno-Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
1 shared publication- Kai He
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
1 shared publication
Latest Publications
- Open Access
- 15 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (33) , eadv6902
USP30 inhibition augments mitophagy to prevent T cell exhaustion
The exhaustion of tumor-infiltrating CD8 + T cells poses a substantial challenge in cancer immunotherapy, with mitochondrial health essential for sustaining T cell functionality. Mitophagy, a critical process for mitochondrial quality control, is severely impaired in exhausted CD8 + T cells, yet the underlying mechanisms remain unclear. We identified ubiquitin-specific protease 30 (USP30), a mitochondrial deubiquitinase that inhibits mitophagy, as a key factor up-regulated in exhausted CD8 + T cells. Notably, prolonged antigen stimulation triggers the T cell receptor and nuclear factor of activated T cell 1 signaling, which drives the transcriptional up-regulation of USP30. Excitingly, our interventions targeting USP30 through genetic deletion or pharmacological inhibition effectively restored mitophagy, improved mitochondrial fitness, and rejuvenated CD8 + T cell effector functions. These interventions reinvigorated antitumor responses and markedly suppressed tumor growth. Our findings establish USP30 as a critical regulator of mitophagy and a promising therapeutic target for reversing T cell exhaustion and enhancing the efficacy of cancer immunotherapy.
- 15 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (33) , eadv6902
Open AccessUSP30 inhibition augments mitophagy to prevent T cell exhaustion
The exhaustion of tumor-infiltrating CD8 + T cells poses a substantial challenge in cancer immunotherapy, with mitochondrial health essential for sustaining T cell functionality. Mitophagy, a critical process for mitochondrial quality control, is severely impaired in exhausted CD8 + T cells, yet the underlying mechanisms remain unclear. We identified ubiquitin-specific protease 30 (USP30), a mitochondrial deubiquitinase that inhibits mitophagy, as a key factor up-regulated in exhausted CD8 + T cells. Notably, prolonged antigen stimulation triggers the T cell receptor and nuclear factor of activated T cell 1 signaling, which drives the transcriptional up-regulation of USP30. Excitingly, our interventions targeting USP30 through genetic deletion or pharmacological inhibition effectively restored mitophagy, improved mitochondrial fitness, and rejuvenated CD8 + T cell effector functions. These interventions reinvigorated antitumor responses and markedly suppressed tumor growth. Our findings establish USP30 as a critical regulator of mitophagy and a promising therapeutic target for reversing T cell exhaustion and enhancing the efficacy of cancer immunotherapy.